CG Invites Co., Ltd. (KOSDAQ:083790)
1,557.00
-3.00 (-0.19%)
At close: Dec 5, 2025
CG Invites Revenue
CG Invites had revenue of 6.13B KRW in the quarter ending September 30, 2025, with 276.19% growth. This brings the company's revenue in the last twelve months to 18.12B, up 225.13% year-over-year. In the year 2024, CG Invites had annual revenue of 7.25B with 48.67% growth.
Revenue (ttm)
18.12B
Revenue Growth
+225.13%
P/S Ratio
6.61
Revenue / Employee
208.30M
Employees
87
Market Cap
119.72B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 7.25B | 2.37B | 48.67% |
| Dec 31, 2023 | 4.88B | 557.33M | 12.90% |
| Dec 31, 2022 | 4.32B | -38.05B | -89.80% |
| Dec 31, 2021 | 42.38B | 12.15B | 40.21% |
| Dec 31, 2020 | 30.22B | 16.22B | 115.78% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.50T |
| Celltrion | 3.90T |
| Yuhan | 2.14T |
| Hanmi Pharm. | 1.47T |
| SK Biopharmaceuticals | 675.41B |
| Sam Chun Dang Pharm. | 220.74B |
| ALTEOGEN | 202.18B |
| LigaChem Biosciences | 159.27B |